Utility of TP53 in Breast Carcinoma Immunophenotypes

Abstract

Breast cancer is a heterogeneous disease and has significant variability in presentation, treatment response, and prognosis. The management of carcinoma breast is currently based on immunophenotypes and Tumour Nodes Metastasis (TNM) staging. The aim of the study is to review the literature and to look for treatment guidelines of carcinoma breast, the role of immunophenotypes in treatment of carcinoma breast, TP53 mutation in breast cancer, and the relationship of TP53 mutation with immunophenotypes, histological grade, efficacy of chemotherapy, and BRCA (Breast Cancer gene) mutation. Pubmed database was researched and a total of 510 articles were analysed. A total of one meta-analysis, one randomised controlled trial, one literature review, nine prospective studies, and three retrospective studies were included for further analysis. It was observed that TP53 mutation is associated with poor overall survival. It was also found to be inversely associated with the Estrogen Receptor (ER) status and so it was seen more commonly in basal type and HER2/neu enriched breast cancer. There is a need for further studies to establish the definite association between TP53 and immunophenotypes so that TP53 alone can be used as a guide for management in carcinoma breast at low resource centres.

Case Report On Management and outcome of Cholangiocarcinoma

“…According to the diagnosis, the patient got medical treatment in an emergency situation, and the patient life was secure. [5][6][7][8][9][10][11] According to the literature that is now accessible, the incidence of tumours typically ranges from 0.7 percent to 11.7 percent, but in recent years, a progressive rise has been noticed, which may be attributed to the ageing population and developments in medical technology and equipment.12-20 According to estimates, 10% of cancer survivors in the US received at least one new primary cancer diagnosis between 1973 and 2000; this percentage has been increasing recently. In terms of the number of primary malignant tumours, MPM with two types of main malignant tumours is typical, whereas MPM with three or fewer types of primary malignant tumours is uncommon.…”

Study of Clinical Profile of Carcinoma Breast and Prognostic Significance of Serum Lactate Dehydrogenase as Tumor Marker in Carcinoma Breast

“…al. focussed on utility of TP53 in breast carcinoma immunophenotypes [15]. Related studies by Laddha et.…”

Doppler Indıces Evaluatıon In Malıgnant Breast Lesıons: A Revıew

“…They concluded that spectral color doppler is a reliable technique in predicting malignancy of BI-RADS 3 breast masses. Few of the related studies on breast malignancies were reviewed [25][26][27][28].…”